[go: up one dir, main page]

MX2019002248A - Proteina de union al factor h modificada. - Google Patents

Proteina de union al factor h modificada.

Info

Publication number
MX2019002248A
MX2019002248A MX2019002248A MX2019002248A MX2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A
Authority
MX
Mexico
Prior art keywords
modified
binding protein
factor binding
fhbp
modified factor
Prior art date
Application number
MX2019002248A
Other languages
English (en)
Other versions
MX420767B (es
Inventor
M Tang Christoph
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2019002248A publication Critical patent/MX2019002248A/es
Publication of MX420767B publication Critical patent/MX420767B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una proteína modificada de unión al factor H (la fHbp), que comprende la fHbp, o una variante de la misma, modificada con la adición de al menos un bucle peptídico exógeno; y ácido nucleico asociado, composiciones y usos. La invención se refiere, además, al tratamiento o prevención de una infección o colonización patógena de un sujeto mediante el uso de la proteína modificada de unión al factor H (la fHbp).
MX2019002248A 2016-08-31 2017-08-31 Proteina de union al factor h modificada MX420767B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (2)

Publication Number Publication Date
MX2019002248A true MX2019002248A (es) 2019-09-18
MX420767B MX420767B (es) 2025-02-10

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002248A MX420767B (es) 2016-08-31 2017-08-31 Proteina de union al factor h modificada

Country Status (13)

Country Link
US (1) US12497432B2 (es)
EP (1) EP3506934A1 (es)
JP (1) JP7525093B2 (es)
KR (1) KR102643280B1 (es)
CN (1) CN109890412B (es)
AU (1) AU2017319218B2 (es)
BR (1) BR112019003957A2 (es)
CA (1) CA3035159A1 (es)
GB (2) GB201614687D0 (es)
IL (1) IL265078B2 (es)
MX (1) MX420767B (es)
WO (1) WO2018042178A1 (es)
ZA (1) ZA201901862B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2022071291A1 (ja) * 2020-09-29 2022-04-07 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
IN202321021121A (es) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
SI2353608T1 (sl) * 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003300841B2 (en) * 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CA2540896C (en) * 2003-10-02 2015-06-02 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
DE602005025647D1 (de) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
BRPI0607374B8 (pt) * 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
ES2532946T3 (es) * 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
EP2296699A4 (en) * 2008-05-30 2013-11-13 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army POLYVALENT MENINGOCOCCULAR FUEL WITH NATIVE OUTER MEMBRANE VESICLES, METHOD OF MANUFACTURE AND USE
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
CA2733943A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
SMT202000366T1 (it) * 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
CN102711814A (zh) * 2009-04-30 2012-10-03 奥克兰儿童医院及研究中心 一种嵌合h因子结合蛋白(fhbp)及其使用方法
CN104650241A (zh) * 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
CN102917730A (zh) * 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
WO2011110634A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
CN110845585A (zh) * 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
CA2803239A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
PE20140173A1 (es) * 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
US10596246B2 (en) * 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
EP4043029A1 (en) * 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) * 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
US9802987B2 (en) * 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
EP3041502A2 (en) * 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EA034954B1 (ru) * 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CN119613509A (zh) * 2014-07-23 2025-03-14 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US20170326220A1 (en) * 2014-11-28 2017-11-16 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
JP7010961B2 (ja) * 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法

Also Published As

Publication number Publication date
GB201614687D0 (en) 2016-10-12
US20220112249A1 (en) 2022-04-14
AU2017319218B2 (en) 2021-10-28
CN109890412A (zh) 2019-06-14
KR102643280B1 (ko) 2024-03-05
BR112019003957A2 (pt) 2019-06-25
MX420767B (es) 2025-02-10
AU2017319218A1 (en) 2019-04-18
GB2568440B (en) 2022-08-17
GB2568440A (en) 2019-05-15
CA3035159A1 (en) 2018-03-08
US12497432B2 (en) 2025-12-16
ZA201901862B (en) 2020-09-30
IL265078B2 (en) 2023-08-01
IL265078A (es) 2019-04-30
IL265078B1 (en) 2023-04-01
NZ751995A (en) 2024-03-22
GB201903866D0 (en) 2019-05-08
EP3506934A1 (en) 2019-07-10
CN109890412B (zh) 2025-04-04
JP7525093B2 (ja) 2024-07-30
WO2018042178A1 (en) 2018-03-08
AU2017319218A2 (en) 2019-05-02
KR20190064577A (ko) 2019-06-10
JP2019526261A (ja) 2019-09-19

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
EA202190983A1 (ru) Новое антитело к с-kit
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2019002248A (es) Proteina de union al factor h modificada.
EA201990071A1 (ru) Композиция пептидной вакцины
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
MX2017003117A (es) Particula tipo virus de flavivirus.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2020008125A (es) Composiciones que comprenden berberina.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
PH12020551618A1 (en) Erenumab compositions and uses thereof
AR106981A1 (es) Una composición antimicrobiana
MX2021015961A (es) Moleculas novedosas.
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
CL2021001138A1 (es) L-triyodotironina (t3) para uso en la limitación de la obstrucción microvascular
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
EA201890209A1 (ru) Композиция, содержащая танины
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2021001361A (es) Composicion liquida de fibrinogeno humano.